ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Haematology series | Risk stratification in MDS"
Episode Synopsis
For patients with myelodysplastic syndrome, or MDS, their therapy options vary considerably depending on their prognosis and risk of developing AML. Today we discuss risk stratification systems and their rationale, and consider their utility in clinical practice. To answer our questions on this topic, we welcome Professor Detlaf Haase, medical director of the special diagnostic laboratories at the clinic for hematology & medical oncology in at the University Medical Center in Göttingen, Germany.
References
Greenberg, et al. Blood. 2012 Sep 20; 120(12): 2454–2465
Montalban-Bravo & Garcia-Manero. Am J Hematol. 2018 Jan;93(1):129-147
This series is supported by educational grants from Servier Pharmaceuticals LLC and Takeda, who have had no influence on the content or choice of faculty.
References
Greenberg, et al. Blood. 2012 Sep 20; 120(12): 2454–2465
Montalban-Bravo & Garcia-Manero. Am J Hematol. 2018 Jan;93(1):129-147
This series is supported by educational grants from Servier Pharmaceuticals LLC and Takeda, who have had no influence on the content or choice of faculty.
More episodes of the podcast Oncology Knowledge into Practice Podcast
The ESMO 2022 Clinical Practice Guidelines for use of systemic therapy in advanced thyroid care
21/03/2023
Working together in the management of thyroid cancer: An oncologist and pathologist in conversation
23/09/2022
Tissue is Never the Issue
27/06/2022
Thyroid cancer: testing for biomarkers
01/04/2022
In God we trust